Australia's Amplia Therapeutics rises on approval for cancer treatment study
** Shares of drug developer Amplia Therapeutics ATX.AX
rise as much as 4.2% to A$0.125
** Co receives https://www.asx.com.au/asxpdf/20220513/pdf/458yyhyhp2m4ns.pdf
ethics clearance to conduct the Phase 2 clinical trial of its
Focal Adhesion Kinase inhibitor in first-line patients with
advanced pancreatic cancer
** More than 350,000 shares change hands, compared with the
30-day average of about 165,000 shares
** Stock down ~27.3% YTD, as of last close
(Reporting by Upasana Singh in Bengaluru)
((Upasana.Singh@thomsonreuters.com))
Recent news on Amplia Therapeutics
See all newsBrief: Amplia Therapeutics Signs Collaboration And Supply Agreement With Lilly
Australia's Amplia rises to 4-month high on Eli Lilly cancer drug trial collaboration
Brief: Amplia Therapeutics Says Warwick Tong Will Retire As Board Chairman
Brief: Amplia Therapeutics Reports Four Additional Complete Responses And Improved Overall Survival Data In Accent Pancreatic Cancer Trial
Brief: Amplia Therapeutics Requests Trading Halt Pending Clinical Trial Results Announcement